One of the key fiduciary duties that agents have towards their principal is to act in a manner which furthers the interest of the principal and hence is beneficial for the principal. Considering that the CEO is the agent of the shareholders who eventually own the company , hence the CEO must act in a manner which tends to maximise the returns for shareholders. It is imperative to note that since the company essentially has a perpetual life, hence decision making by CEO should assist wealth creation not only in the short run but also the long run. Further, it has been seen in that excessive focus on the short run essentially tends to lead to lapses in the long term wealth creation. With regards to the situation at hand, keeping the weight loss pill on the shelf would result in short term gains for the shareholders in terms of dividends. But the lawsuits and subsequent growth in incidence of sufferers would bring about bad press for the company and would have an adverse impact on the reputation and brand equity. Besides, the company may have to spend incremental money in settling various potential lawsuits. Additionally, the decision to continue the pills in the market could have adverse regulatory impact which would have future implications in terms of launch of new drugs going forward. The above analysis clearly highlights that if as the CEO, I decide now to withdraw the pills, then the short gains in the form of dividend would have significant adverse impact in the near future. This is especially relevant considering the nature of the business where customer trust is of utmost importance especially when the drug lacks FDA approval. Hence, as the CEO, it makes sense to decide to take the faulty weight loss pill off the shelf. This might lead to loss of profits in the short term but would ensure that the brand is not adversely impacted. Besides, the customer trust would not be broken. Also, withdrawing the drug in the present would an opportunity to replace the existing drug with a superior version which does not have side effects. This option would not be available in case there is widespread incidence of side effects related to the pill. Hence, maximisation of shareholderwealth in the long run is
supported by the decision to withdraw the pill from the market. Therefore, this is the recommended course of action in order to comply with fiduciary duty towards shareholders.